FRESENIUS KABI
caring for life

Fresenius Kabi USA Nutrition

Admixture Stability Reference Guide



Pediatrics

The data presented within was obtained from the Medical Affairs Department at Fresenius Kabi USA.

How to use this guide:

- Admixture tables are ordered from the lowest concentration of SMOFlipid or Omegaven to the highest concentration and show the final concentrations of the tested admixtures.
- The formulations were tested with the maximum electrolyte content in the additives table and were found to be physically stable. A variety of formulations were tested. Only those formulations that were stable are included in this reference guide.
- Each formulation represents the minimum concentration required of each individual macronutrient to ensure stability. For example, for an admixture to be stable with a final concentration of SMOFlipid 2.1%, the final concentration of TrophAmine® must be at least 2.9% and the final concentration of dextrose must be at least 17.2%.
- SMOFlipid- and Omegaven-containing parenteral nutrition (PN) admixtures with TrophAmine 10% and Omegaven-containing PN admixtures with Premasol 10% have an 11-day stability (9 days refrigerated at 2°C to 8°C [36° to 46°F] followed by 48 hours at room temperature from 20°C to 25°C [68° to 77°F]). SMOFlipid-containing PN admixtures with Premasol 10% have a 10-day stability (9 days refrigerated at 2°C to 8°C [36°F to 46°F] followed by 24 hours at room temperature from 20°C to 25°C [68°F to 77°F]).
- Admixture stability with SMOFlipid and Omegaven was tested by visual inspection, pH, lipid globule size distribution, and mean lipid droplet diameter in compliance with USP <729> standards. No microbiological or chemical tests were conducted. Results are only valid for the branded products listed at the time of testing.
- Additions to the PN admixtures should be evaluated by a pharmacist for compatibility. If it is deemed advisable to introduce additives, use strict aseptic techniques to avoid microbial contamination.
- For detailed information on the data presented in this guide, please contact Fresenius Kabi Medical Affairs at 1-800-551-7176, Option 4.

SMOFlipid®
Lipid Injectable Emulsion, USP 20%

Pediatric amino acids

Admixtures tested with **SMOFlipid** and **TrophAmine** 10%, macronutrient final concentrations (%)

11-day admixture stability (9 days refrigerated followed by 48 hours at room temperature)

Admixtures[a]			
SMOFlipid 20%	2.1%	3.2%	3.6%
TrophAmine 10%	2.9%	4.3%	4.8%
Dextrose 70%	17.2%	21.6%	10.3%
Volume (mL)	280	280	250
Micronutrients			
Sodium chloride (mEq/kg/day)	5	2	2
Potassium acetate (mEq/kg/day)	4	2	2
Calcium gluconate (mEq/kg/day)	8	2	2
Magnesium sulfate (mEq/kg/day)	0.5	0.3	0.3
Sodium phosphate (mmol/kg/day)	2	1	1
INFUVITE® PEDiatric (mL/day) (Baxter)	3.25	3.25	3.25
Selenium (selenious acid) (mcg/kg/day) (American Regent)	2	2	2
Zinc sulfate (mcg/kg/day) (American Regent)	400	250	250
Copper (cupric chloride) (mcg/kg/day) (Hospira)	20	20	20
Chromium (chromic chloride) (mcg/kg/day) (Hospira)	0.3	0.2	0.2
Manganese sulfate (mcg/kg/day) (American Regent)	1	1	1
Cysteine hydrochloride[b] (mg/kg/day) (Exela Pharma Sciences)	160	0	0

[a]SMOFlipid admixture 2.1% concentration was based on a 2-kg infant; SMOFlipid admixtures 3.2% and 3.6% concentrations were based on a 3-kg infant.
[b]Cysteine was only added to SMOFlipid admixture 2.1% concentration; only evaluated in admixture based on a 2-kg infant.
Any significant change in pH from additives not listed compared to what has been evaluated in this study may affect compatibility.



Admixtures tested with **SMOFlipid** and **Premasol** 10%, macronutrient final concentrations (%)

10-day admixture stability (9 days refrigerated followed by 24 hours at room temperature)

Admixtures[a]			
SMOFlipid 20%	2.3%	3%	3.2%
Premasol 10%	3%	3%	4.3%
Dextrose 70%	10.9%	25%	21.6%
Volume (mL)	200	360	280
Micronutrients			
Sodium chloride 23.4% (mEq/kg/day)	2	5	2
Potassium acetate (mEq/kg/day)	2	4	2
Calcium gluconate 10% (mEq/kg/day)	2	4	2
Magnesium sulfate 50% (mEq/kg/day)	0.3	0.5	0.3
Sodium phosphate (mmol/kg/day)	1	2	1
INFUVITE® PEDiatric (mL/day) (Vial 1 and Vial 2) (Baxter)	3.25	5	3.25
Multitrace-4® Neonatal[b] (Trace Elements) (mL/day) (American Regent)	0.3	0.4	0.6

[a]SMOFlipid admixture 2.3% concentration was based on a 1.5-kg infant; SMOFlipid admixture 3% concentration was based on a 3.6-kg infant; SMOFlipid admixture 3.2% concentration was based on a 3-kg infant.
[b]Neonatal Multitrace: each 1 mL contains: zinc (1.5 mg), copper (0.1 mg), manganese (25 mcg), and chromium (0.85 mcg).
Any significant change in pH from additives not listed compared to what has been evaluated in this study may affect compatibility.

Infuse admixtures containing SMOFlipid immediately. Infusion must be complete within 24 hours after removal from refrigeration. Discard any remaining admixture.

Omegaven®
(fish oil triglycerides) injectable emulsion



Pediatric amino acids

Admixtures tested with **Omegaven** and **TrophAmine** 10%, macronutrient final concentrations (%)

11-day admixture stability (9 days refrigerated followed by 48 hours at room temperature)

Omegaven 10%	0.4%	0.7%	0.7%	0.8%	0.8%	0.9%	1%	1%	1.1%	1.2%	1.3%	1.4%	1.9%
TrophAmine 10%	0.8%	1.4%	2.9%	2.4%	3%	2.7%	1%	3%	4.3%	4.8%	3.2%	2.7%	3.2%
Dextrose 70%	5.8%	12.5%	17.2%	6.9%	10.9%	16.8%	8.6%	25%	21.6%	10.3%	14.6%	16.8%	14.6%

Electrolytes and additives in **Omegaven**-containing PN admixtures with **TrophAmine** 10%

Micronutrients	Range (weight-based dosing: based on a 1.5-4.5 kg infant)
Sodium chloride	2 - 5 mEq/kg
Potassium acetate	2 - 4 mEq/kg
Calcium gluconate	2 - 4 mEq/kg/day
Magnesium sulfate	0.3 - 0.5 mEq/kg
(Inorganic) Sodium phosphate	1 - 2 mmol/kg Phos (1.33 - 2.66 mEq/kg Na)
INFUVITE® PEDiatric (Vial 1 and Vial 2) (Baxter)	3.25 - 5 mL
Selenium (selenious acid) (American Regent)	2 mcg/kg
Zinc sulfate (American Regent)	250 - 400 mcg/kg
Copper (cupric chloride) (Hospira)	20 mcg/kg
Chromium (chromic chloride) (Hospira)	0.2 - 0.3 mcg/kg
Manganese sulfate (American Regent)	1 mcg/kg
Cysteine hydrochloride[a] (Exela Pharma Sciences)	0 - 160 mg/kg

[a]Cysteine was only added to Omegaven admixture 0.7% concentration with TrophAmine 10%; only evaluated in admixture based on a 2-kg infant.
Any significant change in pH from additives not listed compared to what has been evaluated in this study may affect compatibility.

Admixtures tested with **Omegaven** and **Premasol** 10%, macronutrient final concentrations (%)

11-day admixture stability (9 days refrigerated followed by 48 hours at room temperature)

Admixtures[a]							
Omegaven 10%	0.7%	0.8%	0.8%	0.9%	1%	1%	1.4%
Premasol 10%	2.9%	2.4%	3%	2.7%	1%	3%	2.7%
Dextrose 70%	17.2%	6.9%	10.9%	16.8%	8.6%	25%	16.8%
Volume (mL)	280	250	200	500	250	360	500
Micronutrients							
Sodium chloride (mEq/kg/day)	5	5	2	5	2	5	5
Potassium acetate (mEq/kg/day)	4	4	2	4	2	4	4
Calcium gluconate (mEq/kg/day)	8	4	2	4	2	4	4
Magnesium sulfate (mEq/kg/day)	0.5	0.5	0.3	0.5	0.3	0.5	0.5
Sodium phosphate (mmol/kg/day)	2	2	1	2	1	2	2
INFUVITE® PEDiatric (mL/day) (Baxter)	3.25	3.25	3.25	3.25	3.25	5	3.25
Selenium (selenious acid) (mcg/kg/day) (American Regent)	2	2	2	2	2	2	2
Zinc sulfate (mcg/kg/day) (American Regent)	400	400	400	250	400	250	250
Copper (cupric chloride) (mcg/kg/day) (Hospira)	20	20	20	20	20	20	20
Chromium (chromic chloride) (mcg/kg/day) (Hospira)	0.3	0.3	0.3	0.2	0.3	0.2	0.2
Manganese sulfate (mcg/kg/day) (American Regent)	1	1	1	1	1	1	1
Cysteine hydrochloride[b] (mg/kg/day) (Exela Pharma Sciences)	160	0	0	0	0	0	0

[a]Formulations based on infants weighing 2 kg (Omegaven admixture 0.7% concentration and Omegaven admixture 0.8% concentration/Premasol 2.4% concentration), 1.5 kg (Omegaven admixture 0.8% concentration/Premasol 3% concentration), 4.5 kg (Omegaven admixtures 0.9% and 1.4% concentrations), 2.5 kg (Omegaven admixture 1% concentration/Premasol 1% concentration), and 3.6 kg (Omegaven admixture 1% concentration/Premasol 3% concentration) in the admixture table above.
[b]Cysteine only added to Omegaven admixture 0.7% concentration; only evaluated in admixture based on a 2-kg infant.
Any significant change in pH from additives not listed compared to what has been evaluated in this study may affect compatibility.

Per the Omegaven Prescribing Information: start the infusion of admixtures containing Omegaven immediately. If not used immediately, admixtures may be stored for up to 6 hours at room temperature or up to 24 hours under refrigeration. Complete the infusion within 24 hours after removal from storage. Any remaining contents of a partly used PN container must be discarded. Follow the instructions of each product included in the admixture.

SMOFlipid®
Lipid Injectable Emulsion, USP 20%

Please scan this QR code to see the full Prescribing Information

SMOFLIPID (lipid injectable emulsion), for intravenous use

BRIEF SUMMARY OF PRESCRIBING INFORMATION

This brief summary does not include all the information needed to use SMOFlipid safely and effectively. Please see full prescribing information for intravenous use at https://bit.ly/3os7FMN

INDICATIONS AND USAGE

SMOFlipid is indicated in adult and pediatric patients, including term and preterm neonates, as a source of calories and essential fatty acids for parenteral nutrition (PN) when oral or enteral nutrition is not possible, insufficient, or contraindicated.

DOSAGE AND ADMINISTRATION

The recommended daily dosage and initial and maximum infusion rates for pediatric and adult patients are provided in Table 1. Do not exceed the recommended maximum infusion rate in Table 1. The recommended duration of infusion for SMOFlipid will vary depending on the clinical situation. Adjust the administration flow rate by taking into account the dose being administered, the daily volume/intake, and the duration of the infusion.

SMOFlipid 1000 mL is supplied as a Pharmacy Bulk Package for admixing only and is not for direct infusion. Prior to administration, transfer to a separate PN container for individual patient use. Use a non-vented, non-DEHP 1.2 micron in-line filter during administration. Protect the admixed PN solution from light.

Table 1: Recommended Pediatric and Adult Dosage and Infusion Rate

Age	Nutritional Requirements	Direct Infusion Rate	
	Recommended Initial Dosage and Maximum Dosage	Initial	Maximum
Birth to 2 years of age (including preterm and term neonates*)	Initial 0.5 to 1 g/kg/day not to exceed 3 g/kg/day**	0.1 to 0.2 mL/kg/hour for the first 15 to 30 minutes; gradually increase to the required rate after 30 minutes	0.75 mL/kg/hour
Pediatric patients 2 to <12 years of age	Initial 1 to 2 g/kg/day not to exceed 3 g/kg/day**	0.2 to 0.4 mL/kg/hour for the first 15 to 30 minutes; gradually increase to the required rate after 30 minutes	0.75 mL/kg/hour
Pediatric patients 12 to 17 years of age	Initial 1 g/kg/day not to exceed 2.5 g/kg/day**	0.2 to 0.4 mL/kg/hour for the first 15 to 30 minutes; gradually increase to the required rate after 30 minutes	0.75 mL/kg/hour
Adults	1 to 2 g/kg/day not to exceed 2.5 g/kg/day**	0.2 mL/kg/hour for the first 15 to 30 minutes; gradually increase to the required rate after 30 minutes	0.5 mL/kg/hour

* The neonatal period is defined as including term, post-term, and preterm newborn infants. The neonatal period for term and post-term infants is the day of birth plus 27 days. For preterm infants, the neonatal period is defined as the day of birth through the expected age of delivery plus 27 days (i.e., 44 weeks post-menstrual age).

** Daily dosage should not exceed a maximum of 60% of total energy requirements

CONTRAINDICATIONS

- Known hypersensitivity to fish, egg, soybean, peanut or to any of the active or inactive ingredients in SMOFlipid.
- Severe disorders of lipid metabolism characterized by hypertriglyceridemia (serum triglycerides >1,000 mg/dL).

WARNINGS AND PRECAUTIONS

- Clinical Decompensation with Rapid Infusion of Intravenous Lipid Emulsion in Neonates and Infants.
  In the postmarketing setting, serious adverse reactions including acute respiratory distress, metabolic acidosis, and death have been reported in neonates and infants after rapid infusion of intravenous lipid emulsions. Hypertriglyceridemia was commonly reported.
  Strictly adhere to the recommended total daily dosage; the hourly infusion rate should not exceed 0.75 mL/kg/hour.
  Preterm and small for gestational age infants have poor clearance of intravenous lipid emulsion and increased free fatty acid plasma levels following lipid emulsion infusion.
  Carefully monitor the infant's ability to eliminate the infused lipids from the circulation (e.g., measure serum triglycerides and/or plasma free fatty acid levels). If signs of poor clearance of lipids from the circulation occur, stop the infusion and initiate a medical evaluation.
- Parenteral Nutrition-Associated Liver Disease and Other Hepatobiliary Disorders.
  Risk of Parenteral Nutrition-Associated Liver Disease (PNALD): PNALD, or Intestinal failure-associated liver disease (IFALD), can present as cholestasis or hepatic stenosis and may progress to steatohepatitis with fibrosis and cirrhosis (possibly leading to chronic hepatic failure). The etiology of PNALD is multifactorial; however, intravenously administered phytosterols (plant sterols) contained in plant-derived lipid emulsions, including SMOFlipid, have been associated with development of PNALD.
  In a randomized study of neonates and infants expected to be treated with PN for at least 28 days, parenteral nutrition-associated cholestasis (PNAC), a precursor to PNALD, developed less frequently in SMOFlipid-treated patients than in 100% soybean oil lipid emulsion-treated patients.
  Monitor liver tests in patients treated with SMOFlipid and consider discontinuation or dosage reduction if abnormalities occur.
  Other Hepatobiliary Disorders
  Hepatobiliary disorders including cholecystitis and cholelithiasis have developed in some parenteral nutrition-treated patients without preexisting liver disease. Monitor liver tests when administering SMOFlipid. Patients developing signs of hepatobiliary disorders should be assessed early to determine whether these conditions are related to SMOFlipid use.
- Hypersensitivity Reactions: SMOFlipid contains soybean oil, fish oil, and egg phospholipids, which may cause hypersensitivity reactions. Cross reactions have been observed between soybean and peanut. SMOFlipid is contraindicated in patients with known hypersensitivity to fish, egg, soybean, peanut, or any of the active or inactive ingredients in SMOFlipid. If a hypersensitivity reaction occurs, stop infusion of SMOFlipid immediately and initiate appropriate treatment and supportive measures.
- Infections: Lipid emulsions, such as SMOFlipid, can support microbial growth and are an independent risk factor for the development of catheter-related bloodstream infections. To decrease the risk of infectious complications, ensure aseptic techniques are used for catheter placement, catheter maintenance, and preparation and administration of SMOFlipid. Monitor for signs and symptoms of infection including fever and chills, as well as laboratory test results that might indicate infection (including leukocytosis and hyperglycemia). Perform frequent checks of the intravenous catheter insertion site for edema, redness, and discharge.
- Fat Overload Syndrome: This is a rare condition that has been reported with intravenous lipid emulsions and is characterized by a sudden deterioration in the patient's condition (e.g., fever, anemia, leukopenia, thrombocytopenia, coagulation disorders, hyperlipidemia, hepatomegaly, deteriorating liver function, and central nervous system manifestations such as coma). A reduced or limited ability to metabolize lipids, accompanied by prolonged plasma clearance (resulting in higher lipid levels), may result in this syndrome. Although fat overload syndrome has been most frequently observed when the recommended lipid dose or infusion rate was exceeded, cases have also been described when the lipid formulation was administered according to instructions.
  If signs or symptoms of fat overload syndrome occur, stop SMOFlipid. The syndrome is usually reversible when the infusion of the lipid emulsion is stopped.
- Refeeding Syndrome: Administering PN to severely malnourished patients may result in refeeding syndrome, which is characterized by the intracellular shift of potassium, phosphorus, and magnesium as patients become anabolic. Thiamine deficiency and fluid retention may also develop. To prevent these complications, closely monitor severely malnourished patients and slowly increase their nutrient intake.
- Hypertriglyceridemia: The use of SMOFlipid is contraindicated in patients with hypertriglyceridemia with serum triglyceride concentrations >1,000 mg/dL.
  Patients with conditions such as inherited lipid disorders, obesity, diabetes mellitus, or metabolic syndromes have a higher risk of developing hypertriglyceridemia with the use of SMOFlipid. In addition, patients with hypertriglyceridemia may have worsening of their hypertriglyceridemia with administration of SMOFlipid. Excessive dextrose administration may further increase such risk.
  Evaluate patients' capacity to metabolize and eliminate the infused lipid emulsion by measuring serum triglycerides before the start of infusion (baseline value) and regularly throughout treatment. If triglyceride levels are above 400 mg/dL in adults, stop the SMOFlipid infusion and monitor serum triglyceride levels to avoid clinical consequences of hypertriglyceridemia such as pancreatitis. In pediatric patients with hypertriglyceridemia, lower triglyceride levels (i.e., below 400 mg/dL) may be associated with adverse reactions. Monitor serum triglyceride levels to avoid potential complications with hypertriglyceridemia such as pancreatitis, lipid pneumonitis, and neurologic changes, including kernicterus.
  To minimize the risk of new or worsening of hypertriglyceridemia, assess high-risk patients for their overall energy intake including other sources of lipids and dextrose, as well as concomitant drugs that may affect lipid and dextrose metabolism.
- Aluminum Toxicity: SMOFlipid contains no more than 25 mcg/L of aluminum. Prolonged PN administration in patients with renal impairment may result in aluminum reaching toxic levels. Preterm infants are at greater risk because their kidneys are immature, and they require large amounts of calcium and phosphate solutions, which contain aluminum. Patients with impaired kidney function, including preterm infants, who receive parenteral levels of aluminum at greater than 4 to 5 mcg/kg/day can accumulate aluminum at levels associated with central nervous system and bone toxicity. Tissue loading may occur at even lower rates of administration.
- Essential Fatty Acid Deficiency: Treatment-emergent cases of moderate or severe essential fatty acid deficiency (EFAD) (defined as the triene [Mead acid] to tetraene [arachidonic acid] ratio >0.2 and >0.4, respectively) were not observed in pediatric clinical trials of SMOFlipid up to 28 days. However, cases of EFAD have been reported in adults and pediatric patients in the postmarketing period with the use of SMOFlipid. The median time to onset was greater than 28 days among cases that reported time to onset. Monitor patients for laboratory evidence (e.g., abnormal fatty acid levels) and clinical symptoms of EFAD (e.g., skin manifestations and poor growth) because these signs may emerge before laboratory evidence of EFAD is confirmed. Laboratory testing using the triene to tetraene ratio may not be adequate to diagnose EFAD, and assessment of individual fatty acid levels may be needed. Ensure patients are receiving recommended dosages of SMOFlipid to prevent EFAD.
- Monitoring/Laboratory Tests: Throughout treatment monitor serum triglycerides, fluid and electrolyte status, blood glucose, liver and kidney function, coagulation parameters, and complete blood count including platelets.
  The lipids contained in SMOFlipid may interfere with some laboratory blood tests (e.g., hemoglobin, lactate dehydrogenase [LDH], bilirubin, and oxygen saturation) if blood is sampled before lipids have cleared from the bloodstream. Conduct these blood tests at least 6 hours after stopping the infusion. SMOFlipid contains vitamin K that may counteract anticoagulant activity.

ADVERSE REACTIONS

Most common adverse drug reactions >1% of adult patients who received SMOFlipid from clinical trials were nausea, vomiting, hyperglycemia, flatulence, pyrexia, abdominal pain, increased blood triglycerides, hypertension, sepsis, dyspepsia, urinary tract infection, anemia, and device-related infection.

Less common adverse reactions in ≤1% of adult patients who received SMOFlipid were dyspnea, leukocytosis, diarrhea, pneumonia, cholestasis, dysgeusia, increased blood alkaline phosphatase, increased gamma-glutamyltransferase, increased C-reactive protein, tachycardia, liver function test abnormalities, headache, pruritis, dizziness, rash, and thrombophlebitis.

The most common adverse drug reactions in >1% of pediatric patients who received SMOFlipid were anemia, vomiting, gamma-glutamyltransferase increased, nosocomial infection, cholestasis, pyrexia, C-reactive protein increased, hyperbilirubinemia, abdominal pain, bilirubin conjugated increased, diarrhea, tachycardia, thrombocytopenia, hyperglycemia, and sepsis.

Less common adverse reactions in ≤1% of pediatric patients who received SMOFlipid were decreased hematocrit, metabolic acidosis, increased blood triglycerides, infection, increased blood alkaline phosphatase, increased alanine aminotransferase, fluid overload, hypertension, hypertriglyceridemia, and rash.

The following adverse reactions have been identified during post-approval use of SMOFlipid in countries where it is registered. Cardiac disorders: palpitations; General disorders and administration site conditions: chills, chest pain, malaise; Hepatobiliary disorders: cholestasis; Infections and infestations: infection; Metabolism and nutrition disorders: fatty acid deficiency; Respiratory, thoracic and mediastinal disorders: dyspnea; Skin and subcutaneous tissue disorders: hyperhidrosis; Vascular disorders: phlebitis.

To report SUSPECTED ADVERSE REACTIONS, contact Fresenius Kabi USA, LLC at 1-800-551-7176, option 5, or FDA at 1-800-FDA-1088 or www.fda.gov/medwatch.

DRUG INTERACTIONS

Soybean and olive oils in SMOFlipid contain vitamin K, which may counteract the anticoagulant activity of vitamin K antagonists such as warfarin. In patients who receive concomitant SMOFlipid and warfarin, increase monitoring of laboratory parameters for anticoagulant activity.

USE IN SPECIFIC POPULATIONS

- Pregnancy and Lactation: Administration of the recommended dose of SMOFlipid is not expected to cause major birth defects, miscarriage, or other adverse maternal or fetal outcomes. No animal reproduction studies have been conducted with SMOFlipid. Administration of the recommended dose of SMOFlipid is not expected to cause harm to a breastfed infant. There are no data on the presence of SMOFlipid in human or animal milk or its effects on milk production.
- Pediatric Use: The safety and effectiveness of SMOFlipid have been established as a source of calories and essential fatty acids for parenteral nutrition when oral or enteral nutrition is not possible, insufficient, or contraindicated in pediatric patients, including term and preterm neonates. Use of SMOFlipid in neonates is supported by evidence from short-term (i.e., 1- to 4-week) studies, and one study following neonates beyond 4 weeks. Use of SMOFlipid in older pediatric patients is supported by evidence from a short-term (i.e., <28 days) study in pediatric patients 28 days to 12 years of age and additional evidence from studies in adults. The most common adverse reactions in SMOFlipid-treated pediatric patients were anemia, vomiting, gamma-glutamyltransferase increased, and nosocomial infection. PNALD, also referred to as IFALD, has been reported in pediatric patients who received SMOFlipid for more than 2 weeks. PNAC (a precursor to PNALD) was reported less frequently in SMOFlipid-treated patients compared to soybean oil lipid emulsion-treated patients in Pediatric Study 1. Although clinically significant cases of EFAD were not observed during short-term use in pediatric clinical studies, cases of EFAD have been reported with the use of SMOFlipid in the postmarketing setting. Monitor pediatric patients for laboratory evidence of EFAD because they may be particularly vulnerable to neurologic complications if adequate amounts of essential fatty acids are not provided. In the post marketing setting, clinical decompensation with rapid infusion of intravenous lipid emulsion in neonates and infants, sometimes fatal has been reported. Because of immature renal function, preterm infants receiving prolonged treatment with SMOFlipid may be at risk for aluminum toxicity.
- Geriatric Use: Energy expenditure and requirements may be lower for older adults than younger patients. Of the 354 adult patients in clinical studies of SMOFlipid, 35% were >65 years of age and 10% were >75 years of age. No overall differences in the safety and efficacy of SMOFlipid were observed between these patients and younger patients, and other reported clinical experience has not identified differences in responses between the elderly and younger patients, but greater sensitivity in some older patients cannot be ruled out.

OVERDOSAGE

In the event of an overdose, serious adverse reactions may result. Stop the SMOFlipid infusion until triglyceride levels have normalized and symptoms have abated. The effects are usually reversible by stopping the lipid infusion. If medically appropriate, further intervention may be indicated. Lipids are not dialyzable from plasma.

Omegaven®
(fish oil triglycerides) injectable emulsion

Please scan this QR code to see the full Prescribing Information

OMEGAVEN (fish oil triglycerides) injectable emulsion, for intravenous use

BRIEF SUMMARY OF PRESCRIBING INFORMATION

This brief summary does not include all the information needed to use Omegaven safely and effectively. Please see full prescribing information for Omegaven (fish oil triglycerides) injectable emulsion for intravenous use at https://qrco.de/bd4nRi.

INDICATIONS AND USAGE

Omegaven is indicated as a source of calories and fatty acids in pediatric patients with parenteral nutrition-associated cholestasis (PNAC).

Limitations of Use

Omegaven is not indicated for the prevention of PNAC. It has not been demonstrated that Omegaven prevents PNAC in parenteral nutrition (PN)-dependent patients.

It has not been demonstrated that the clinical outcomes observed in patients treated with Omegaven are a result of the omega-6: omega-3 fatty acid ratio of the product.

DOSAGE AND ADMINISTRATION

Protect the admixed PN solution from light. Prior to administration, correct severe fluid and electrolyte disorders and measure serum triglycerides to establish a baseline level. Initiate dosing in PN-dependent pediatric patients as soon as direct or conjugated bilirubin levels are 2 mg/dL or greater. The recommended nutritional requirements of fat and recommended dosage of Omegaven to meet those requirements for pediatric patients are provided in Table 1, along with recommendations for the initial and maximum infusion rates. Do not exceed the maximum infusion rate in Table 1. Administer Omegaven until direct or conjugated bilirubin levels are less than 2 mg/dL or until the patient no longer requires PN. Use a 1.2 micron in-line filter during administration.

Table 1: Recommended Pediatric Dosage and Infusion Rate

Nutritional Requirements	Direct Infusion Rate	
Recommended Initial Dosage and Maximum Dosage	Initial	Maximum
1 g/kg/day; this is also the maximum daily dose	0.2 mL/kg/hour for the first 15 to 30 minutes; gradually increase to the required rate after 30 minutes	1.5 mL/kg/hour

CONTRAINDICATIONS

Omegaven is contraindicated in patients with known hypersensitivity to fish or egg protein or to any of the active ingredients or excipients, severe hemorrhagic disorders due to a potential effect on platelet aggregation, severe disorders of lipid metabolism characterized by hypertriglyceridemia (serum triglyceride concentrations greater than 1,000 mg/dL).

WARNINGS AND PRECAUTIONS

- Clinical Decompensation with Rapid Infusion of Lipid Injectable Emulsions in Neonates and Infants
  In the postmarket setting, serious adverse reactions including acute respiratory distress, metabolic acidosis, and death have been reported in neonates and infants after rapid infusion of lipid injectable emulsions. Hypertriglyceridemia was commonly reported. Strictly adhere to the recommended total daily dosage; the hourly infusion rate should not exceed 1.5 mL/kg/hour. Preterm and small for gestational age infants have poor clearance of lipid injectable emulsions and increased free fatty acid plasma levels following infusion. Carefully monitor the infant's ability to eliminate the infused lipids from the circulation (e.g., measure serum triglycerides and/or plasma free fatty acid levels). If signs of poor clearance of lipids from the circulation occur, stop the infusion and initiate a medical evaluation.
- Hypersensitivity Reactions: Omegaven contains fish oil and egg phospholipids, which may cause hypersensitivity reactions. Signs or symptoms of a hypersensitivity reaction may include: tachypnea, dyspnea, hypoxia, bronchospasm, tachycardia, hypotension, cyanosis, vomiting, nausea, headache, sweating, dizziness, altered mentation, flushing, rash, urticaria, erythema, fever, or chills. If a hypersensitivity reaction occurs, stop infusion of Omegaven immediately and initiate appropriate treatment and supportive measures.
- Infections: The risk of infection is increased in patients with malnutrition-associated immunosuppression, long-term use and poor maintenance of intravenous catheters, or immunosuppressive effects of other conditions or concomitant drugs. To decrease the risk of infectious complications, ensure aseptic technique in catheter placement and maintenance, as well as in the preparation and administration of Omegaven. Monitor for signs and symptoms of early infections including fever and chills, laboratory test results that might indicate infection (including leukocytosis and hyperglycemia), and frequently inspect the intravenous catheter insertion site for edema, redness, and discharge.
- Fat Overload Syndrome: A reduced or limited ability to metabolize lipids accompanied by prolonged plasma clearance may result in this syndrome, which is characterized by a sudden deterioration in the patient's condition including fever, anemia, leukopenia, thrombocytopenia, coagulation disorders, hyperlipidemia, hepatomegaly, deteriorating liver function, and central nervous system manifestations (e.g., coma).
- Refeeding Syndrome: Administering PN to severely malnourished patients may result in refeeding syndrome, which is characterized by the intracellular shift of potassium, phosphorus, and magnesium as the patient becomes anabolic. Thiamine deficiency and fluid retention may also develop. To prevent these complications, closely monitor severely malnourished patients and slowly increase their nutrient intake.
- Hypertriglyceridemia: Impaired lipid metabolism with hypertriglyceridemia may occur in conditions such as inherited lipid disorders, obesity, diabetes mellitus, and metabolic syndrome. Serum triglyceride levels greater than 1,000 mg/dL have been associated with an increased risk of pancreatitis. To evaluate the patient's capacity to metabolize and eliminate the infused lipid emulsion, measure serum triglycerides before the start of infusion (baseline value), and regularly throughout treatment. If hypertriglyceridemia (triglycerides greater than 250 mg/dL in neonates and infants or greater than 400 mg/dL in older children) develops, consider stopping the administration of Omegaven for 4 hours and obtain a repeat serum triglyceride level. Resume Omegaven based on new result as indicated.
- Aluminum Toxicity: Omegaven contains no more than 25 mcg/L of aluminum. Aluminum may reach toxic levels with prolonged parenteral administration if kidney function is impaired. Preterm infants are particularly at risk because their kidneys are immature, and they require large amounts of calcium and phosphate solutions, which contain aluminum. Patients with impaired kidney function, including preterm infants, who receive parenteral levels of aluminum at greater than 4 to 5 mcg/kg/day accumulate aluminum at levels associated with central nervous system and bone toxicity. Tissue loading may occur at even lower rates of administration.
- Monitoring and Laboratory Tests: Routine Monitoring: Monitor serum triglycerides, fluid and electrolyte status, serum osmolarity, blood glucose, liver and kidney function, coagulation parameters, and complete blood count including platelets throughout treatment. Essential Fatty Acids: Monitoring patients for laboratory evidence of essential fatty acid deficiency (EFAD) is recommended. Laboratory tests are available to determine serum fatty acids levels. Reference values should be consulted to help determine adequacy of essential fatty acid status.
- Interference with Laboratory Tests: The lipids contained in Omegaven may interfere with some laboratory blood tests (e.g., hemoglobin, lactate dehydrogenase, bilirubin, and oxygen saturation) if blood is sampled before lipids have cleared from the bloodstream. Lipids are normally cleared after a period of 5 to 6 hours once the lipid infusion is stopped.

ADVERSE REACTIONS

The most common adverse drug reactions (>15%) are: vomiting, agitation, bradycardia, apnea and viral infection.

Clinical Trials Experience

The safety database for Omegaven reflects exposure in 189 pediatric patients (19 days to 15 years of age) treated for a median of 14 weeks (3 days to 8 years) in two clinical trials.

Adverse reactions that occurred in more than 5% of patients who received Omegaven and with a higher incidence than the comparator group are: vomiting, agitation, bradycardia, apnea, viral infection, erythema, rash, abscess, neutropenia, hypertonia and incision site erythema. Patients had a complicated medical and surgical history prior to receiving Omegaven treatment and the mortality was 13%. Underlying clinical conditions prior to the initiation of Omegaven therapy included prematurity, low birth weight, necrotizing enterocolitis, short bowel syndrome, ventilator dependence, coagulopathy, intraventricular hemorrhage, and sepsis.

Twelve (6%) Omegaven-treated patients were listed for liver transplantation (1 patient was listed 18 days before treatment, and 11 patients after a median of 42 days [range: 2 days to 8 months] of treatment); 9 (5%) received a transplant after a median of 121 days (range: 25 days to 6 months) of treatment, and 3 (2%) were taken off the waiting list because cholestasis resolved.

One hundred thirteen (60%) Omegaven-treated patients reached DBil levels less than 2 mg/dL and AST or ALT levels less than 3 times the upper limit of normal, with median AST and ALT levels for Omegaven-treated patients at 89 and 65 U/L, respectively, by the end of the study.

Median hemoglobin levels and platelet counts for Omegaven-treated patients at baseline were 10.2 g/dL and 173 x 10^9/L, and by the end of the study these levels were 10.5 g/dL and 217x 10^9/L, respectively. Adverse reactions associated with bleeding were experienced by 74 (39%) of Omegaven-treated patients.

Median glucose levels at baseline and the end of the study were 86 and 87 mg/dL for Omegaven-treated patients, respectively. Hyperglycemia was experienced by 13 (7%) Omegaven-treated patients.

Median triglyceride levels at baseline and the end of the study were 121 mg/dL and 72 mg/dL for Omegaven-treated patients respectively. Hypertriglyceridemia was experienced by 5 (3%) Omegaven-treated patients.

The triene:tetraene (Mead acid:arachidonic acid) ratio was used to monitor essential fatty acid status in Omegaven-treated patients only in Study 1 (n = 123). The median triene:tetraene ratio was 0.02 (interquartile range: 0.01 to 0.03) at both baseline and the end of the study. Blood samples for analysis may have been drawn while the lipid emulsion was being infused and patients received enteral or oral nutrition.

Postmarketing Experience

The following adverse reaction has been identified with use of Omegaven in another country. Life-threatening hemorrhage following a central venous catheter change was reported in a 9 month-old infant with intestinal failure who received PN with Omegaven as the sole lipid source; he had no prior history of bleeding, coagulopathy, or portal hypertension.

To report SUSPECTED ADVERSE REACTIONS, contact Fresenius Kabi USA, LLC, at 1-800-551-7176, option 5, or FDA at 1-800-FDA-1088 or www.fda.gov/medwatch.

DRUG INTERACTIONS

Prolonged bleeding time has been reported in patients taking antiplatelet agents or anticoagulants and oral omega-3 fatty acids. Periodically monitor bleeding time in patients receiving Omegaven and concomitant antiplatelet agents or anticoagulants.

USE IN SPECIFIC POPULATIONS

- Pregnancy: There are no available data on Omegaven use in pregnant women to establish a drug-associated risk of major birth defects, miscarriage, or adverse maternal or fetal outcomes. Animal reproduction studies have not been conducted with fish oil triglycerides. The estimated background risk of major birth defects and miscarriage in the indicated population is unknown. All pregnancies have a background risk of birth defect, loss, or other adverse outcomes. In the US general population, the estimated background risk of major birth defects and miscarriage in clinically recognized pregnancies is 2% to 4% and 15% to 20%, respectively.
- Lactation: No data available regarding the presence of fish oil triglycerides from Omegaven in human milk, the effects on the breastfed infant, or the effects on milk production. Lactating women receiving oral omega-3 fatty acids have been shown to have higher levels of omega-3 fatty acids in their milk. The developmental and health benefits of breastfeeding should be considered along with the mother's clinical need for Omegaven, and any potential adverse effects of Omegaven on the breastfed infant.
- Pediatric Use: The safety of Omegaven was established in 189 pediatric patients (19 days to 15 years of age). The most common adverse reactions in Omegaven-treated patients were vomiting, agitation, bradycardia, apnea and viral infection. In the postmarketing setting, clinical decompensation with rapid infusion of lipid injectable emulsions in neonates and infants, sometimes fatal has been reported. Preterm neonates and infants who receive treatment with Omegaven may be at risk of aluminum toxicity and other metabolic abnormalities.
- Geriatric Use: Clinical trials of Omegaven did not include patients 65 years of age and older.

OVERDOSAGE

In the event of an overdose, serious adverse reactions may occur. Stop the infusion of Omegaven until triglyceride levels have normalized and any symptoms have abated. The effects are usually reversible by stopping the lipid infusion. If medically appropriate, further intervention may be indicated. Lipids are not dialyzable from serum.

If you have any questions, please contact medical information at 1.800.551.7176 (option 4) or email Nutrition.MedInfo.USA@fresenius-kabi.com.

FRESENIUS KABI
caring for life

Fresenius Kabi USA, LLC
Three Corporate Drive,
Lake Zurich, IL 60047
Phone: 1.888.386.1300
www.fresenius-kabi.com/us

Fresenius Kabi USA Nutrition